Prueba farmacogenómica para pacientes con trastorno del espectro autista: ¿cuáles son las ventajas?
Los trastornos del espectro autista (TEA) son sumamente comunes. Para darnos una idea del impacto del autismo en la sociedad, se estima que uno de cada 68 niños estadounidenses presenta algún tipo de trastorno del espectro autista.
Improved Antidepressant Remission in Major Depression via a Pharmacokinetic Pathway Polygene Pharmacogenetic Report
The World Health Organization predicts that major depressive disorder (MDD) will become a leading cause of disability globally by 2030.1) Reducing the burden of this ease from MDD is a public health priority, yet it appears the per capita level of disability from MDD globally is increasing.2) Antidepressants have assisted treatment of more severe MDD, with demonstrated superiority over placebo.3) Unfortunately, 30-50% of patients do not respond (at least a halving of the depression rating scale score),4) to their first antidepressant trial.5-10) Remission (return of the rating scale to normative levels; e.g., 17-item Hamilton Depression Rating Scale [HDRS] ≤7) is clinically a more translatable efficacy measure as those who respond but fail to remit tend to relapse.4,11) Remission not response is the pathway to recovery from MDD.
The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis
Major depressive disorder (MDD) is a highly prevalent and disabling mental illness affecting more than 350 million people globally as theleading cause of disability worldwide (WHO, 2017).
Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial
Major depressive disorder (MDD) is a leading cause of disability worldwide [1]. Actions to reduce the impact of depression on patients, families and healthcare systems are thus a public health priority.
Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: A large, patient- and rater-blinded, randomized, controlled study
Current prescribing practices for major depressive disorder (MDD) produce limited treatment success. Although pharmacogenomics may improve outcomes by identifying genetically inappropriate medications, studies to date were limited in scope.
Combinatorial Pharmacogenomic Testing Improves Outcomesfor Older Adults WithDepression
Geriatric depression, which affects approximately 5% of older adults (age ≥65 years) in the United States,1,2 places substantial burdens on function, quality of life, and healthcare resources. In 2017, 2.2% of U.S. men and 3.5% of women age 65 years or older had experienced a major depressive episode in the past year, according to the U.S. Substance Abuse and Mental Health Services Administration.3 Although major depressive disorder (MDD) episodes are less prevalent in older adults than in younger age groups,1 up to 15% of community-dwelling people in this age category experience clinically significant depressive symptoms, with higher rates of MDD and depressive symptomatology among those in medical settings.1 Depression among older adults is linked with longer length of illness, more frequent MDD recurrences, and a greater risk of comorbidities.4,5 In this population, depression is the psychiatric illness most closely associated with suicide,6 the rate of which climbed to a high of 17.2 per 100,000 individuals in 2018.7 A broad range of clinical and social factors adds complexity to its presentation and medical management. Therefore, the diagnosis and treatment of geriatric depression warrant special focus.
The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis
To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for patients with major depressive disorder (MDD).
Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials
Antidepressants are recommended for use in the treatment of moderate-to-severe major depression [1], but many patients fail to benefit from these medications. Between 30 and 50% of patients with major depressive disorder (MDD) do not respond to their first antidepressant trial [2] and remission rates are as low as 37.5% [3].
Effect of Pharmacogenetic-Based Decision Support Tools in Improving Depression Outcomes: A Systematic Review
Major depressive disorder (MDD) is one of the most prevalent mood disorders worldwide. The World Health Organization (WHO) reports that more than 300 million people from all age groups are affected by depression worldwide.1 Globally, depression is considered one of the major causes of disability
Cost–effectiveness of combinatorial pharmacogenomic testing for depression from the Canadian public payer perspective
Depression is a significant health and economic burden in Canada. In addition to the impact of depression on patients’ health and quality of life [1], it costs the Canadian economy more than CAD $32 billion annually [2].The cost of depression stems directly from increased healthcare resource utilization and indirectly as a result of increased disability and absenteeism [3,4]. For example, the direct and indirect per-patient costs were 3.5 and three-times higher, respectively,